Boston Scientific to Acquire Elutia's EluPro and CanGaroo Drug-Eluting Bioenvelopes for $88 Million to Strengthen Cardiac Rhythm Management Portfolio

September 9,Medical Technology CompanyElutiaAnnouncing itsEluPro and CanGarooDrug-Eluting Bio-CoatingSell toBoston Scientific, with a total transaction amount of 88 million US dollars (approximately 630 million RMB).

EluPro, as the first antibiotic-eluting biological sheath, loaded with rifampicin and minocycline, can prevent bacterial colonization and promote the regeneration of healthy vascularized tissue. It has been approved by the FDA for marketing to prevent postoperative complications in patients with implanted cardiac devices and can also be used in pain management, epilepsy, and other fields.

Boston Scientific previously collaborated with Elutia to distribute bio-sheath products, and this acquisition will further strengthen its position inCardiac Rhythm Management FieldAndMedtronicIn competition, EluPro may have clinical operational advantages over TYRX.

The transaction is expected to be completed byQ4 2025Upon completion, the ownership of these products, used to protect patients with implanted medical devices, will be transferred to Boston Scientific.

According to the company's press release, this transaction will enable Elutia toEliminate Outstanding Debt, and has basically resolved the litigation issues related to its previously divested orthopedic biologics business.

Moreover, the proceeds from the transaction will also be used forAdvance and commercialize its NXT-41 breast reconstruction product line。

After the transaction is completed, Elutia plans to focus its resources onSimpliDerm Product Series and Drug-Eluting Pipeline, the goal is valueThe $1.5 Billion U.S. Breast Reconstruction Market。

Dr. Randy Mills, CEO of ElutiaRepresentation："This transaction highlights the value of its proprietary drug-eluting biotechnology platform and enables the company to complete the development and commercialization of its near-term product pipeline without equity dilution."